Advertisement
"Rich has strong leadership skills, extensive experience managing financedepartments and significant expertise in the capital markets," stated CharlesW. Bishop, PhD, Cytochroma's President and CEO. "He joins Cytochroma at acritical inflection point in its growth. The Company now has multiple VitaminD-based therapies in clinical development and it requires a seasoned CFO whocan play a key role in expanding and evolving the corporate and financialinfrastructure."
Advertisement
Previous to Cytochroma, Mr. Wieland was Executive Vice President & CFO ofAdvanced Life Sciences where he helped that company list on the NASDAQ stockmarket in 2005 and prepared it for Sarbanes-Oxley implementation. Mr. Wielandalso led the successful initial public offering of MediChem Life Sciences,where he served as Executive Vice President & CFO. Earlier in his career, Mr.Wieland held senior level financial and management positions at BioGenexLaboratories, Cancer Treatment Centers, Fujisawa USA, LyphoMed and Procter &Gamble. He holds an MBA from Washington University and a Bachelor's degree inAccounting and Finance from Monmouth College.
"Cytochroma is at an exciting time in its development and has anoutstanding management team in place," stated Mr. Wieland. "As CFO, I lookforward to working with this team to build a strong and sustainable specialtypharmaceutical company."
Cytochroma has a diverse portfolio of Vitamin D-based therapeuticsdesigned to treat disorders related to abnormal or insufficient Vitamin Dmetabolism in chronic kidney disease (CKD) patients. These new products willaddress target markets that are expected to grow significantly, reaching morethan $1.2 billion annually by 2010 in North America alone. Cytochroma hasthree lead product candidates in development for CKD patients: CTA018 andCTAP201 are being developed for the treatment of secondary hyperparathyroidism(SHPT), while CTAP101 is being developed for the treatment of Vitamin Dinsufficiency.
About Chronic Kidney Disease
According to the National Kidney Foundation (NKF), more than nine millionNorth American patients suffer from moderate CKD (Stages 3 and 4) to severeCKD (Stage 5). Stages 3 and 4 are characterized by progressively decreasingkidney function as measured by glomerular filtration rate. In Stage 5, kidneyfunction is altogether absent and patients require regular dialysis or kidneytransplant for survival. An estimated 70-90% of CKD patients have Vitamin Dinsufficiency, which can lead to SHPT and resultant debilitating bonediseases. Mounting evidence continues to link Vitamin D insufficiency with CKDprogression and increased morbidity and mortality in CKD patients. CKD is mostfrequently caused by diabetes or hypertension, both of which are consequencesof a growing obesity epidemic in countries worldwide.
About Cytochroma
Cytochroma is a clinical stage specialty pharmaceutical company focused ondeveloping and commercializing proprietary products to treat and prevent theclinical consequences of Vitamin D insufficiency and SHPT associated with CKD.The Company's Vitamin D-based therapeutics are designed to safely andeffectively treat patients with Stage 3, 4 or 5 CKD. In addition, Cytochromais developing novel therapies to treat hyperphosphatemia in these samepatients. For more information, please visit www.cytochroma.com.
SOURCE Cytochroma Inc.
